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EVPI was €1368 at a value of the ceiling ratio of €20,000. EVPPI
analysis showed that utilities had the largest contribution to the
overall EVPI. The partial EVPI for this subset of input parame-
ters was €517. Incorporating the newly collected data on utili-
ties into the model reduced the overall EVPI to €563 and the
partial EVPI for the utility input parameter to approximately €0.
CONCLUSIONS: Collecting additional information on utilities
strongly reduced the overall and partial EVPI. At the population
level, the value of collecting additional data on utilities out-
weighed the costs of data collection. Value of information analy-
sis proved to be useful to determine the parameters for which
additional data collection is most beneﬁcial.
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OBJECTIVES: There are currently no well-validated Patient
Reported Outcome (PRO) tools to measure dyspnea in COPD
patients that have been accepted for label claims. Guidelines for
measuring PROs to support label claims encourage patient input
to deﬁne endpoints for clinical trials. This study was designed to
understand COPD patients’ experience of dyspnea, and inform
strategy for measuring PRO endpoints in clinical trials.
METHODS: Seventy-eight individuals (55% male; mean age 58
years) with moderate to severe COPD (MRC grades III-V) across
6 countries participated in interviews/focus groups, describing
their breathing difﬁculties, severity, impacts and ﬂuctuations.
Themes were identiﬁed from a systematic content review of the
transcripts, and further reviewed by an additional 18 patients.
SESULTS: Six distinct sensations of dyspnea were reported, with
patients across multiple cultures demonstrating the ability to dif-
ferentiate between sensations. Patients reported a high level of
diurnal and day-to-day variation in both the nature and severity
of symptoms. A conceptual model was developed based on this
qualitative work and discussion with an expert panel of six clin-
icians and three psychometric experts. Patients conﬁrmed the
multi-sensational nature of dyspnea that is also suggested within
the literature—“a subjective experience of breathing discomfort
that consists of qualitatively distinctive sensations that vary in
intensity”. However, existing measures evaluate dyspnea as a
one-dimensional symptom (a single construct of shortness of
breath) with a broad recall period (one to two weeks). CON-
CLUSIONS: The model showed that a daily diary (with symp-
toms differentiated and assessed by patient-generated descriptive
language) is more relevant for evaluating patients’ experience of
dyspnea in clinical trials. This work demonstrates the value of
extensive, multi-cultural patient input during early stages of PRO
development to ensure that the endpoint strategy for supporting
labelling claims adequately ﬁts the conceptual model for the
patient experience of that condition.
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OBJECTIVES: Tiotropium is a once-daily inhaled anticholiner-
gic maintenance treatment with demonstrated effectiveness in
chronic obstructive pulmonary disease (COPD). We aimed to
compare persistence of tiotropium-use with other respiratory
drugs in COPD in current clinical practice. METHODS: The
PHARMO database includes, among others, drug-dispensing
and hospital discharge records for >2 million subjects in The
Netherlands. All probable COPD-patients were identiﬁed by new
respiratory drug use (age >54 yrs) or COPD-hospitalizations.
New users of tiotropium, ipratropium, long-acting beta-agonists
(LABAs), or ﬁxed combination of inhaled corticosteroids and
LABA (ICS&LABA), in 1998–2003, were included in the study.
Persistence was assessed quarterly during the ﬁrst year of follow-
up. Patients with a proportion of days covered (PDC) ≥80%
were considered persistent. Persistence was analysed using gen-
eralised estimating equations model. RESULTS: About 37% of
new users of tiotropium continued treatment for one year, com-
pared with 14% for ipratropium, 13% for LABA, and 17% for
ICS&LABA. Multivariate analyses showed that tiotropium-users
were 2–3 times more persistent with their therapy than patients
using ipratropium (relative risk [RR]: 2.0; 95% conﬁdence inter-
val [CI]: 1.8–2.3), LABA (RR: 2.9; 95%CI: 2.4–3.6), or
ICS&LABA (RR: 2.4; 95%CI: 2.1–2.8), respectively. Male
gender, age >70 years, pulmonologist as ﬁrst prescriber, prior 
use of other respiratory drugs, and previous hospitalization 
for COPD were all associated with enhanced persistence with 
the initial drug-therapy. CONCLUSIONS: Persistence with
tiotropium was increased compared to other respiratory drugs
in COPD in clinical practice. Additional research is required 
to understand the reasons for these higher persistence levels.
Enhanced treatment persistence may offer beneﬁts to both
patients and society in terms of decreased morbidity and costs.
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OBJECTIVES: Long-term patient adherence to treatment is the
key issue in the efﬁcacy of sublingual immunotherapy (SLIT). To
help clinicians to manage SLIT patients and improve their adher-
ence, a speciﬁc questionnaire: QUARTIS, has been developed
and validated. METHODS: Relevant concepts were identiﬁed
through a combination of literature research and clinician and
patient interviews. After comprehension tests with patients, two
pilot versions, one for patients beginning SLIT (QUARTIS-Start)
and one for patients undergoing SLIT (QUARTIS-Follow-up),
were drawn up and pilot tested in clinical practice. A cross-
sectional observational study including 191 adult patients with
allergic rhinitis beginning SLIT and 381 undergoing SLIT was
conducted to reduce the questionnaires, create their scoring 
and assess their psychometric properties. The ability of the
QUARTIS-Follow-up to predict patients’ intentions to complete
SLIT, motivations to continue the course of SLIT, and adherence
